Article
Amylyx's ALS drug faces tough FDA scrutiny ahead of 2nd advisory panel meeting
Rating:
0.0
Views:
31
Likes:
1
Library:
1
An FDA independent advisory panel will conveneĀ again to discuss Amylyx Pharmaceuticals' contested amyotrophic lateral sclerosis (ALS) drug, a | After a March rejection by an FDA advisory panel, the committee will meet again to discuss Amylyx's application for its ALS drug. But for this second round, FDA staffers have pointed out some similar issues with the data as last time.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value